Panobinostat
Primary Peritoneal Cancer
Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 73/ 100
Competitive context
55 Active assets in the Primary Peritoneal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE AbbVie | Phase 3 | BB |
Trebananib Amgen | Phase 3 | BB |
Imnn-001 Imunon | Phase 3 | B |
Niraparib Imunon | Phase 3 | B |
Nivolumab Regeneron Pharmaceuticals | Phase 3 | B |
View all 50 →
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →